Active Ingredient: Pegaspargase
Pegaspargase is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
For this indication, competent medicine agencies globally authorize below treatments:
Intramuscular
2,000 - 2,500 [iU]
From 2,000 To 2,500 [iU] once every 14 day(s)
Pegaspargase is usually administered as part of combination chemotherapy protocols with other antineoplastic agents.
The recommended dose in patients with a body surface area (BSA) ≥0.6 m² and who are ≤21 years of age is 2,500 U of pegaspargase (equivalent to 3.3 ml pegaspargase)/m² body surface area every 14 days.
Children with a body surface area <0.6 m² should receive 82.5 U of pegaspargase (equivalent to 0.1 ml pegaspargase)/kg body weight every 14 days.
Unless otherwise prescribed, the recommended posology in adults aged >21 years is 2,000 U of pegaspargase (equivalent to 2.67 ml pegaspargase)/m² body surface area every 14 days.
Treatment may be monitored based on the trough serum asparaginase activity measured before the next administration of pegaspargase. If asparaginase activity values fail to reach target levels, a switch to a different asparaginase preparation could be considered.
Pegaspargase can be given by intramuscular (IM) injection or intravenous (IV) infusion.
For smaller volumes, the preferred route of administration is intramuscular. When pegaspargase is given by intramuscular injection the volume injected at one site should not exceed 2 ml in children and adolescents and 3 ml in adults. If higher volume is given, the dose should be divided and given at several injection sites.
Intravenous
2,000 - 2,500 [iU]
From 2,000 To 2,500 [iU] once every 14 day(s)
Pegaspargase is usually administered as part of combination chemotherapy protocols with other antineoplastic agents.
The recommended dose in patients with a body surface area (BSA) ≥0.6 m² and who are ≤21 years of age is 2,500 U of pegaspargase (equivalent to 3.3 ml pegaspargase)/m² body surface area every 14 days.
Children with a body surface area <0.6 m² should receive 82.5 U of pegaspargase (equivalent to 0.1 ml pegaspargase)/kg body weight every 14 days.
Unless otherwise prescribed, the recommended posology in adults aged >21 years is 2,000 U of pegaspargase (equivalent to 2.67 ml pegaspargase)/m² body surface area every 14 days.
Treatment may be monitored based on the trough serum asparaginase activity measured before the next administration of pegaspargase. If asparaginase activity values fail to reach target levels, a switch to a different asparaginase preparation could be considered.
Pegaspargase can be given by intramuscular (IM) injection or intravenous (IV) infusion.
Intravenous infusion of pegaspargase is usually given over a period of 1 to 2 hours in 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
